These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39343427)

  • 1. Incidence of metabolic dysfunction-associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study.
    Kim K; Lee Y; Lee JS; Kim MN; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Jung I; Lee HW
    J Gastroenterol Hepatol; 2024 Dec; 39(12):2845-2852. PubMed ID: 39343427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total choline intake, liver fibrosis and the progression of metabolic dysfunction-associated steatotic liver disease: Results from 2017 to 2020 NHANES.
    Taesuwan S; Kouvari M; McKune AJ; Panagiotakos DB; Khemacheewakul J; Leksawasdi N; Rachtanapun P; Naumovski N
    Maturitas; 2025 Jan; 191():108150. PubMed ID: 39536658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The moderating effect of dietary fiber intake on the association between sleep pattern and liver fibrosis in metabolic dysfunction-associated steatotic liver disease: a study from NHANES.
    Jia G; Jia M; Li C
    BMC Gastroenterol; 2024 Dec; 24(1):457. PubMed ID: 39695427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential Diagnostic Approach Using FIB-4 and ELF for Predicting Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Kang YW; Baek YH; Moon SY
    Diagnostics (Basel); 2024 Nov; 14(22):. PubMed ID: 39594183
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of Risk Factors Associated with Metabolic Dysfunction-Associated Steatotic Liver Disease in Psoriatic Patients.
    Küçük K; Moreno C; Nijmi H; Daoud M; Mintoff D; Willaert F; Benhadou F
    Dermatology; 2024 Nov; ():1-8. PubMed ID: 39536736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study.
    Martínez-Montoro JI; Arranz-Salas I; Gutiérrez-Repiso C; Sánchez-García A; Ocaña-Wilhelmi L; Pinazo-Bandera JM; Fernández-García D; Muñoz-Garach A; Morales-García D; García-Cortés M; García-Fuentes E; Tinahones FJ; Garrido-Sánchez L
    Nutrients; 2024 Nov; 16(22):. PubMed ID: 39599643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between liver and cardiometabolic health in type 1 diabetes.
    Tas E; Vu BK; Mendizabal B; Libman I; Muzumdar R
    Front Endocrinol (Lausanne); 2024; 15():1505430. PubMed ID: 39605938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
    Kwak M; Kim HS; Jiang ZG; Yeo YH; Trivedi HD; Noureddin M; Yang JD
    Hepatology; 2025 Jan; 81(1):228-237. PubMed ID: 38739848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic dysfunction-associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study.
    Park Y; Jung J; Han S; Kim GA
    Aliment Pharmacol Ther; 2024 Dec; 60(11-12):1599-1608. PubMed ID: 39304991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential prevalence and prognostic value of metabolic syndrome components among patients with MASLD.
    Pustjens J; van Kleef LA; Janssen HLA; de Knegt RJ; Brouwer WP
    JHEP Rep; 2024 Dec; 6(12):101193. PubMed ID: 39640221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Dietary Niacin on Metabolic Dysfunction-Associated Steatotic Liver Disease in Mediterranean Subjects: A Population-Based Study.
    Antentas M; Rojo-López MI; Vendrell P; Granado-Casas M; Genua I; Fernandez-Camins B; Rossell J; Niño-Narvión J; Moreira E; Castelblanco E; Ortega E; Vlacho B; Alonso N; Mauricio D; Julve J
    Nutrients; 2024 Nov; 16(23):. PubMed ID: 39683571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Wong RJ; Yang Z; Yeoh A; Do A; Ahmed A; Cheung R
    Am J Gastroenterol; 2024 Sep; 119(9):1841-1848. PubMed ID: 38477465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.
    Kawaguchi T; Fujishima Y; Wakasugi D; Io F; Sato Y; Uchida S; Kitajima Y
    J Gastroenterol; 2024 Dec; 59(12):1120-1132. PubMed ID: 39392481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its association with arterial stiffness in adolescents: Results from the EVA4YOU study.
    Nairz J; Messner A; Kiechl SJ; Winder B; Hochmayr C; Granna J; Egger AE; Griesmacher A; Geiger R; Knoflach M; Kiechl-Kohlendorfer U;
    PLoS One; 2024; 19(11):e0314585. PubMed ID: 39602440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemafibrate for treating MASLD complicated by hypertriglyceridaemia: a multicentre, open-label, randomised controlled trial study protocol.
    Iwaki M; Kobayashi T; Nogami A; Ogawa Y; Imajo K; Sakai E; Nakada Y; Koyama S; Kurihashi T; Oza N; Kohira T; Okada M; Yamaguchi Y; Iwane S; Kageyama F; Sasada Y; Matsushita M; Tadauchi A; Murohisa G; Nagasawa M; Sato S; Maeda K; Furuta K; Shigefuku R; Seko Y; Tobita H; Kawata K; Kawanaka M; Sugihara T; Tamaki N; Iwasa M; Kawaguchi T; Itoh Y; Kawaguchi A; Takahashi H; Nakajima A; Yoneda M
    BMJ Open; 2024 Nov; 14(11):e088862. PubMed ID: 39581726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021.
    Yang Z; Li A; Jiang Y; Maidaiti X; Wu Y; Jin Y
    Sci Rep; 2024 Sep; 14(1):22232. PubMed ID: 39333707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uric acid as a potential marker of cardiometabolic risk in children and adolescents with metabolic dysfunction associated steatotic liver disease.
    Zdanowicz K; Kopiczko N; Flisiak-Jackiewicz M; Bobrus-Chociej A; Kowalczuk-Kryston M; Lebensztejn DM
    Clin Exp Hepatol; 2024 Sep; 10(3):188-193. PubMed ID: 39697369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of serum folate and vitamin B
    Zhu J; Liao X; Du L; Lv P; Deng J
    Front Endocrinol (Lausanne); 2024; 15():1426103. PubMed ID: 39703860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.